Plain-English translation of NCT07024615 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This study is testing a new medication called for people with pancreatic cancer that can be surgically removed. The medication works by helping your immune system recognize and attack cancer cells that have a specific protein called Claudin 18.2. You would receive one injection of the medication before surgery, then have chemotherapy afterward — a common approach that doctors hope may help prevent cancer from returning.
Pancreatic cancer is a serious illness, and even after surgery, many patients benefit from chemotherapy to lower the risk of the cancer coming back. Researchers think that this new medication might boost the chemotherapy's effectiveness by activating your immune system to fight cancer cells more powerfully.
You likely qualify if…
You likely don't qualify if…
You would receive an injection of the medication about two weeks before your scheduled pancreatic cancer surgery. After your surgery heals, you would receive chemotherapy treatments (your doctor will choose from three standard options) over about six months. You would have regular clinic visits during this time to monitor your health and manage any side effects, with a final check-in about a month after your chemotherapy ends.
AI-generated summary from trial data · Jun 30, 2026 · Not medical advice
United States